NCT05564221View on ClinicalTrials.gov

A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
Atopic Healthy SubjectsAdult Subjects With Allergic Diseases
Interventions
DRUG

YH35324

Subcutaneous injection of YH35324

DRUG

Placebo

Subcutaneous injection of None of active ingredient

DRUG

Omalizumab

Subcutaneous injection of Omalizumab

Trial Locations (9)

13620

Seoul National University Bundang Hospital, Seongnam-si

14584

Soonchunhyang University Bucheon Hospital, Bucheon-si

16499

Ajou University Hospital, Suwon

01830

Nowon Eulji Medical Center, Seoul

02841

Korea University Anam Hospital, Seoul

03722

Severance Hospital, Seoul

05030

Konkuk University Medical Center, Seoul

05505

Asan Medical Center, Seoul

06591

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY